Establishment Labs (NASDAQ:ESTA) Receives Buy Rating from Needham & Company LLC

Establishment Labs (NASDAQ:ESTA)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research note issued to investors on Friday,Benzinga reports. They currently have a $48.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 29.31% from the stock’s current price.

Several other research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Establishment Labs from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. BTIG Research initiated coverage on shares of Establishment Labs in a research report on Friday, May 16th. They set a “buy” rating and a $62.00 price objective on the stock. Finally, Stephens reaffirmed an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a research note on Thursday, March 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $52.40.

Establishment Labs Stock Down 3.7%

Shares of NASDAQ ESTA opened at $37.12 on Friday. The firm has a market cap of $1.07 billion, a PE ratio of -14.39 and a beta of 0.74. The company has a 50 day simple moving average of $33.79 and a 200 day simple moving average of $37.41. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $52.41.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.13. The firm had revenue of $41.38 million for the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.58) EPS. On average, research analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Several institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB boosted its holdings in Establishment Labs by 32.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock worth $378,000 after purchasing an additional 2,000 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Establishment Labs during the 4th quarter worth approximately $5,494,000. Black Swift Group LLC lifted its position in shares of Establishment Labs by 98.6% during the 4th quarter. Black Swift Group LLC now owns 14,300 shares of the company’s stock worth $659,000 after buying an additional 7,100 shares in the last quarter. Swiss National Bank boosted its stake in shares of Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company’s stock worth $1,774,000 after buying an additional 1,000 shares during the last quarter. Finally, Royce & Associates LP bought a new position in shares of Establishment Labs in the fourth quarter valued at approximately $4,862,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.